CAI Caris Life Sciences, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CAI matters now
Caris Life Sciences, Inc. (CAI) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.99 with -4.92% on the session and $4.80B in market capitalization; recent performance reads 1-month +23.46% and YTD -31.54%.
The latest financial table shown here is Q1 2026, with revenue of $216.2M, net income of $-510.0K, and EPS of $-0.00. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 2.4%.
The latest indexable market news headline is "Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $30.00; recent insider activity includes Knowles Jonathan Kenneth Charles filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
8.79
P/S
5.75
EV/EBITDA
46.24
DCF Value
$-16.56
FCF Yield
2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.7%
Operating Margin
15.9%
Net Margin
3.7%
ROE
6.5%
ROA
2.9%
ROIC
14.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $216.2M | $-510.0K | $-0.00 |
| Q4 2025 | $292.9M | $82.0M | $0.28 |
| FY 2025 | $812.0M | $-538.0M | $-1.90 |
| Q3 2025 | $216.8M | $24.3M | $0.08 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$28.60
Target (Median)
$30.00
Target Range
$21.00 - $38.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.79
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.